Faes Farma Stock

Faes Farma EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Faes Farma (FAE.MC) as of Aug 9, 2026 is 21.84. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 15.55 — a change of 40.41% (higher).

EV/EBIT

21.84

YoY

40.41%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Faes Farma is 2026 21.84 . EV/EBIT (Enterprise Value to EBIT) of Faes Farma was 2025 15.55 . It decreases by 40.41% higher compared to the previous year.

The Faes Farma EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
17.37 base
Jan 1, 2020
11.63 base
Jan 1, 2021
10.97 base
Jan 1, 2022
13.66 base
Jan 1, 2023
12.20 base
Jan 1, 2024
10.15 base
Jan 1, 2025
21.06 base
Jan 1, 2026 (e)
8.99 base
YEARPRICE-TO-EBIT
2026 est 8.99
2025 21.06
2024 10.15
2023 12.20
2022 13.66
2021 10.97
2020 11.63
2019 17.37
2018 12.74
2017 14.89
2016 17.92
2015 16.14
2014 11.32
2013 20.01
2012 14.62
2011 16.78
2010 25.71
2009 -
2008 -
2007 -
2006 -
Access this data via the Eulerpool API

Faes Farma Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Faes Farma's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Faes Farma's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Faes Farma's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Faes Farma grows earnings faster than its peers.

Faes Farma Stock analysis

What does Faes Farma do? The history of Faes Farma SA dates back to 1933, when the company was founded in Barcelona, Spain. The founders had a vision to develop innovative products that would contribute to improving the health and well-being of people. Over the following decades, the company grew continuously and established itself as one of the leading players in the pharmaceutical industry. The business model of Faes Farma SA is focused on the development and marketing of products for the healthcare industry. The company relies on research and development to develop innovative solutions for various therapeutic areas. Faes Farma SA distributes its products worldwide through a network of partners and distributors, with a focus on Europe and Latin America. Faes Farma SA operates in three different divisions. The first division is pharmaceuticals, where the company offers products for various areas such as respiratory diseases, allergies, pain, and inflammation. An important part of this segment is the product Bilastine, which is used for the treatment of allergies and is considered an alternative to antihistamines. The second division is animal health. Here, Faes Farma SA offers products for the treatment of pets, including preparations against fleas, ticks, and worms. One of the most well-known products in this area is the Stangest brand, which is considered the leading brand for animal health in Spain. The third division of Faes Farma SA is the business of medical devices and diagnostics. Here, the company offers a wide range of products for various medical applications, including devices for monitoring vital signs and diagnostics for infectious diseases. Overall, Faes Farma SA is a company with a diversified product portfolio that is of interest to both end consumers and healthcare professionals and pet owners. The company has continuously developed and invested in research and development in recent years to expand its product offering and provide innovative solutions for various medical needs. Faes Farma SA is a company that stands out for its commitment to the development of innovative products and its dedication to the health and well-being of humans and animals. With a strong focus on research and development and a wide distribution network, the company has solidified its position in the pharmaceutical industry and will continue to play an important role in the market. Faes Farma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Faes Farma stock

EV/EBIT (Enterprise Value to EBIT) of Faes Farma is 21.84 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Faes Farma changed from 15.55 to 21.84, representing a 40.41% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Faes Farma since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Faes Farma with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Faes Farma

All Key Metrics — Faes Farma